USA – Biotechnology giant Amgen, valued at US $149.6 billion, has announced a US $1 billion investment to build a second drug substance manufacturing facility in Holly Springs, North Carolina.
This new investment adds to the company’s prior US $550 million commitment to the same location, bringing the total planned investment in the region to over US $1.5 billion.
The new facility will employ cutting-edge technologies and sustainable manufacturing practices, aligning with Amgen’s focus on environmental stewardship.
The first Holly Springs facility, which began operations in 2021, already integrates both conventional and innovative production technologies, enabling Amgen to manufacture a variety of products within a single plant.
This expansion comes at a time of robust financial performance for Amgen, which has experienced impressive revenue growth of 21.25% over the past year.
The new site will create an additional 370 jobs, bolstering the region’s role as a key biomanufacturing hub.
Amgen’s expansion in North Carolina underscores the company’s commitment to meeting the increasing global demand for its innovative therapies.
Robert A. Bradway, Amgen’s CEO, emphasized the importance of this new facility in advancing the company’s global manufacturing network.
North Carolina’s established reputation as a biotech center, combined with its innovative ecosystem and skilled workforce, makes it an attractive location for Amgen’s expansion.
Governor Roy Cooper of North Carolina welcomed the investment, highlighting the state’s growth as a leader in biotechnology.
Amgen, which has been a pioneer in biotechnology for over 40 years, has earned recognition for its innovation.
In 2024, the company was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes.
The company also boasts a strong financial position, offering a 3.23% dividend yield and maintaining a track record of increasing dividends for 14 consecutive years.
In other recent developments, Amgen has made significant progress with its obesity treatment, MariTide, which has shown promising clinical trial results.
Analysts, including TD Cowen, have expressed optimism about MariTide’s potential in the competitive obesity market.
The treatment is also being evaluated for its impact on weight loss and glycemic control in patients with Type 2 diabetes.
